Literature DB >> 20716818

jefA (Rv2459), a drug efflux gene in Mycobacterium tuberculosis confers resistance to isoniazid & ethambutol.

Anuj Kumar Gupta1, Vineel P Reddy, Mallika Lavania, D S Chauhan, K Venkatesan, V D Sharma, A K Tyagi, V M Katoch.   

Abstract

BACKGROUND &
OBJECTIVES: Drug efflux pumps have been contributing factor(s) in the development of multidrug resistance in various clinically relevant bacteria. During efflux pump gene expression studies on mycobacteria, we have found a previously uncharacterized open reading frame (ORF) Rv2459 to be overexpressed in drug stressed conditions. The objective of the present study was to investigate the role of this ORF as a drug efflux pump, which might add new information in our understanding about the alternative mechanisms of drug resistance in mycobacteria.
METHODS: The open reading frame Rv2459 of Mycobacterium tuberculosis encoding a probable drug efflux protein has been cloned using pSD5 E.coli-Mycobacterium shuttle vector and overexpressed in M. tuberculosis H(37)Rv. This ORF was named as jefA. Overexpression of this gene in clones has been verified by real-time reverse transcription PCR. Minimum inhibitory concentrations (MICs) of recombinant as well as non-recombinant clones were determined by resazurin microtitre assay plate method (REMA) with and without efflux pump inhibitors carbonyl cyanide m-chlorophenylhydrazone (CCCP) and verapamil.
RESULTS: In recombinant strains of M. tuberculosis, the overexpression of this gene led to an increase in MIC of anti-tubercular drugs isoniazid and ethambutol when tested by REMA. In the presence of CCCP and verapamil, the recombinant strains showed decrease in MIC for these drugs. Bioinformatic analysis has shown a close relation of JefA protein with drug efflux pumps of other clinically relevant bacteria. In homology derived structure prepared from nearest available model, it was observed that amino acids forming TMH 1, 8 and 11 participated in ethambutol specificity and those forming TMH 2, 7 and 10 participated in isoniazid specificity in JefA. INTERPRETATION &
CONCLUSION: The increased transcription of jefA leads to increased resistance to ethambutol and isoniazid in M. tuberculosis via efflux pump like mechanism and contributes in the development of resistance to these drugs. JefA amino acid sequence is well conserved among clinically important bacterial genera, which further provides evidence of being a potent drug efflux pump. The involvement in drug resistance and very little homology with any of the human proteins makes JefA important to be included in the list of potential drug targets.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20716818

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  17 in total

1.  Protein-protein interaction networks suggest different targets have different propensities for triggering drug resistance.

Authors:  Jyothi Padiadpu; Rohit Vashisht; Nagasuma Chandra
Journal:  Syst Synth Biol       Date:  2011-02-20

2.  Antimycobacterial activity of five efflux pump inhibitors against Mycobacterium tuberculosis clinical isolates.

Authors:  Guilian Li; Jingrui Zhang; Chao Li; Qian Guo; Yi Jiang; Jianhao Wei; Yan Qiu; Xiuqin Zhao; Li-li Zhao; Jianxin Lu; Kanglin Wan
Journal:  J Antibiot (Tokyo)       Date:  2015-10-14       Impact factor: 2.649

3.  Geographical differences associated with single-nucleotide polymorphisms (SNPs) in nine gene targets among resistant clinical isolates of Mycobacterium tuberculosis.

Authors:  Matt Hoshide; Lishi Qian; Camilla Rodrigues; Rob Warren; Tommie Victor; Henry B Evasco; Thelma Tupasi; Valeriu Crudu; James T Douglas
Journal:  J Clin Microbiol       Date:  2013-06-19       Impact factor: 5.948

4.  Possible Binding of Piperine in Mycobacterium tuberculosis RNA Polymerase and Rifampin Synergism.

Authors:  Letícia Sayuri Murase; João Vítor Perez de Souza; Katiany Rizzieri Caleffi Ferracioli; Rosilene Fressatti Cardoso; Jean Eduardo Meneguello; Flavio Augusto Vicente Seixas; Laíse Adriane Hegeto; Regiane Bertin de Lima Scodro; Vera Lucia Dias Siqueira
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 5.  Energy metabolism and drug efflux in Mycobacterium tuberculosis.

Authors:  Philippa A Black; Robin M Warren; Gail E Louw; Paul D van Helden; Thomas C Victor; Bavesh D Kana
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

Review 6.  Mycobacterium tuberculosis Major Facilitator Superfamily Transporters.

Authors:  Ping Li; Yinzhong Gu; Jiang Li; Longxiang Xie; Xue Li; Jianping Xie
Journal:  J Membr Biol       Date:  2017-08-29       Impact factor: 1.843

7.  Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis.

Authors:  Diana Machado; Isabel Couto; João Perdigão; Liliana Rodrigues; Isabel Portugal; Pedro Baptista; Bruno Veigas; Leonard Amaral; Miguel Viveiros
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

8.  Tetrandrine reverses drug resistance in isoniazid and ethambutol dual drug-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  Zhe Zhang; Jie Yan; Kaijin Xu; Zhongkang Ji; Lanjuan Li
Journal:  BMC Infect Dis       Date:  2015-03-25       Impact factor: 3.090

9.  Efflux pump gene expression in multidrug-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  Guilian Li; Jingrui Zhang; Qian Guo; Yi Jiang; Jianhao Wei; Li-li Zhao; Xiuqin Zhao; Jianxin Lu; Kanglin Wan
Journal:  PLoS One       Date:  2015-02-19       Impact factor: 3.240

10.  Mycobacterium tuberculosis Is Resistant to Isoniazid at a Slow Growth Rate by Single Nucleotide Polymorphisms in katG Codon Ser315.

Authors:  Rose E Jeeves; Alice A N Marriott; Steven T Pullan; Kim A Hatch; Jon C Allnutt; Irene Freire-Martin; Charlotte L Hendon-Dunn; Robert Watson; Adam A Witney; Richard H Tyler; Catherine Arnold; Philip D Marsh; Timothy D McHugh; Joanna Bacon
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.